Merlo Ignacio G, Fratantoni Eugenia, de Santibañes Martín, Ardiles Victoria, Sanchez Clariá Rodrigo, Pekolj Juan, de Santibañes Eduardo, Mazza Oscar
Servicio de Cirugía General, Sector de Cirugía Hepatobiliopancreática, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. E-mail:
Servicio de Cirugía General, Sector de Cirugía Hepatobiliopancreática, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Medicina (B Aires). 2021;81(5):800-807.
Pancreatic cancer is an aggressive disease associated with poor results regarding long term survival. Surgical treatment along with new oncologic treatments have improved the survival of these patients in international experience reports. The aim of this study was to describe overall survival and disease-free survival after pancreatectomy for pancreatic ductal adenocarcinoma. A retrospective study of consecutive patients undergoing pancreatic resection due to PDAC or undifferentiated carcinoma from January 2010 to January 2020 in a single tertiary center was performed. Overall, 242 patients underwent complete pancreatic resections for pancreatic ductal adenocarcinoma or undifferentiated carcinoma. Median overall survival was 22.8 months (95% CI: 19.5-29) and survival at 1, 3 and 5 years were 72%, 32.5% and 20.8% respectively. The median disease-free survival was 13.8 months (95% CI: 12-17.6) and 1, 3- and 5-years disease-free survival were 56.1%, 21.8% and 19.4% respectively. The groups of patients that completed adjuvant treatment showed a better overall survival (p < 0.0001).
胰腺癌是一种侵袭性疾病，长期生存率较低。在国际经验报告中，手术治疗与新的肿瘤治疗方法提高了这些患者的生存率。本研究的目的是描述胰腺导管腺癌胰十二指肠切除术后的总生存率和无病生存率。对2010年1月至2020年1月在单一三级中心因胰腺导管腺癌或未分化癌接受胰腺切除术的连续患者进行了一项回顾性研究。总体而言，242例患者因胰腺导管腺癌或未分化癌接受了完整的胰腺切除术。中位总生存期为22.8个月（95%CI：19.5-29），1年、3年和5年生存率分别为72%、32.5%和20.8%。中位无病生存期为13.8个月（95%CI：12-17.6），1年、3年和5年无病生存率分别为56.1%、21.8%和19.4%。完成辅助治疗的患者组总生存率更高（p<0.0001）。
